Semaglutide Microdosing: Doses and Syringe Units

"Microdosing" semaglutide means using weekly doses below the 0.25 mg the label starts everyone on — typically 0.05–0.2 mg — and it is an off-label practice with no efficacy trials behind those weekly amounts. The arithmetic, though, is exactly the same as any other dose: find your vial concentration in mg/mL, divide the dose by it to get millilitres, then multiply by 100 to read the number off a U-100 syringe.

TL;DR — key takeaways

• Microdosing is off-label. The approved Ozempic and Wegovy schedules begin at 0.25 mg once weekly; no marketed product offers a smaller weekly step, and no weight-loss trial tested weekly doses under 0.25 mg.
• The 0.25 mg start is a tolerability dose, not a treatment dose. It exists to let the gut adjust, which is why labels hold it for four weeks before stepping up.
• Low doses do less. The one dose-ranging trial that tested very small amounts used daily dosing and found weight loss scaled with the dose — smaller meant less.
• Units depend on concentration, not on the drug name. The same 0.1 mg dose can be 10 units or 2 units depending on the vial strength.

What people mean by "microdosing"

The term is borrowed loosely. In practice it describes drawing a weekly dose smaller than the 0.25 mg starting step — for example 0.1 mg — usually from a compounded multi-dose vial, in the hope of getting appetite suppression with fewer side effects or to stretch a vial further. It is not a recognised clinical protocol. Both FDA-approved semaglutide products, Ozempic for type 2 diabetes and Wegovy for weight management, start at 0.25 mg once weekly and provide no smaller pen increment, so any sub-0.25 mg weekly dose is measured out manually from a vial — which is where the unit arithmetic below comes in.

Why the label starts at 0.25 mg

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It slows gastric emptying and blunts appetite — the same actions that drive early nausea. To let the gut adapt, the label opens with 0.25 mg once weekly purely as an introductory dose and explicitly states it is not effective for glycaemic control or weight loss on its own; it is a launch pad, held for four weeks before stepping to 0.5 mg and beyond.

Semaglutide's elimination half-life is roughly one week, so weekly dosing reaches steady state after about four to five weeks. A smaller weekly dose simply settles at a lower steady-state concentration — the molecule does not behave differently at 0.1 mg, there is just less of it on board.

What the low-dose evidence actually shows

The only randomised trial to probe doses this small was a 52-week phase 2 dose-ranging study that escalated daily semaglutide from 0.05 mg upward. Mean weight loss tracked the dose: about 6% at 0.05 mg/day rising to 11–14% at 0.2–0.4 mg/day, versus 2.3% on placebo. Two caveats apply before mapping that onto microdosing.

• It used daily injections, not the once-weekly regimen the marketed products use, so the numbers do not convert one-to-one to a weekly microdose.
• It confirms the direction every clinician expects: less drug, less effect. Microdosing trades potential efficacy for tolerability, and that trade is not free.

There is no published efficacy trial of weekly semaglutide below 0.25 mg. Anyone choosing a microdose is, by definition, outside the studied range.

Standard start vs a microdose, side by side

The right-hand column is not a recommendation; it describes what microdosing involves so the risks are visible. The smaller the dose, the smaller the draw volume, and the easier it is to misjudge on a syringe.

Low-dose units, visualised

At a fixed vial strength, units scale linearly with the dose — halve the dose and you halve the units. This ladder shows weekly doses from 0.05 mg to 0.25 mg on a 1 mg/mL vial.

The amber bar at 0.25 mg is the lowest labelled dose; everything to its left is a microdose. Notice the perfectly even steps — that linearity is what makes the conversion easy once you know the concentration.

How to turn a low dose into syringe units

The rule never changes: units = (dose ÷ concentration) × 100, because a U-100 syringe holds 100 units in 1 mL. The only variable is the vial's mg/mL strength, which is set when the powder is reconstituted. Here are worked examples across the doses and concentrations a microdose actually involves.

Low-dose reference chart

Weekly microdoses as units on a U-100 syringe, at two common compounded strengths. Always confirm against your own vial label.

At 2.5 mg/mL the microdoses fall to 2–8 units, where a one-unit miscount is a sizeable percentage error. A more dilute vial spreads the same dose over more units and is easier to measure precisely.

How this is calculated

Every figure here rests on two facts: a U-100 syringe holds 100 units per millilitre, and concentration is dose divided by volume. There is no semaglutide-specific constant — the same arithmetic applies to any vialled peptide. We divide the dose by the vial's mg/mL to get the volume, then multiply by 100 for units, and round only to the nearest graduation the syringe actually offers. This is a maths and education tool, not medical advice: the dose itself is a decision for your prescriber, and the low-dose discussion here describes what is and isn't studied rather than endorsing any regimen.

Frequently asked questions